Longeveron Inc Stock Price, News & Analysis

Longeveron (NASDAQ: LGVN) announced progress in its clinical trials, including a Phase 2a trial for Lomecel-B in Alzheimer’s patients, with 50% enrollment achieved. The Japanese PMDA accepted an amended trial design for Aging Frailty, potentially allowing accelerated market entry. The Phase 1/2 HERA trial noted met safety endpoints, showing promise for Lomecel-B. Financially, the company reported $27 million in cash as of June 30, 2022, sufficient to fund operations into 2024, although net losses increased to $5.6 million from $5 million year-over-year.

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology firm, announced that an abstract detailing the Phase 2a trial of Lomecel-B in Alzheimer’s Disease has been accepted for presentation at the Alzheimer’s Association International Conference (AAIC) from July 31 to August 4, 2022. Ongoing enrollment for the trial is noted. Earlier in 2022, a peer-reviewed study confirmed the success of Lomecel-B in a Phase 1b trial, achieving its primary endpoint with good tolerability in patients. The poster presentation is scheduled for August 2, 2022.

Longeveron Inc. (NASDAQ: LGVN) reported its Q1 2022 financial results, highlighting a revenue of $0.4 million, consistent with Q1 2021. Clinical trial revenue increased by 88% to $0.3 million due to reduced COVID-19 travel restrictions, while grant revenue fell 72% to $0.1 million due to the completion of prior trials. R&D expenses rose by 6% to $1.4 million, and G&A expenses increased by 16% to $2.0 million, leading to a net loss of $3.5 million. Cash and short-term investments stood at $30.6 million. The company anticipates sufficient funds to cover expenses into H1 2024.

Longeveron Inc. (NASDAQ: LGVN) announced the resignation of CEO Geoff Green, effective June 1, 2022. K. Chris Min, M.D., Ph.D., the current Chief Medical Officer, will serve as Interim CEO while a nationwide search for a permanent successor takes place. Under Green's leadership, Longeveron progressed significantly, advancing their Lomecel-B therapy into clinical trials. The company specializes in cellular therapies targeting aging-related and life-threatening conditions and is pursuing Phase 1 and 2 trials for multiple indications including Alzheimer’s disease and frailty.

Longeveron Inc. (NASDAQ: LGVN) will release its first quarter 2022 financial results on May 13, 2022, before the U.S. market opens. The management will host a conference call at 8:30 a.m. EST on the same day to discuss the results and provide corporate updates. Longeveron is focused on developing cellular therapies for aging-related and life-threatening conditions. Its lead product, Lomecel-B, is currently in Phase 1 and 2 trials addressing multiple serious conditions. For more, visit longeveron.com.

Longeveron Inc. (NASDAQ: LGVN) announces participation in key events showcasing its commitment to developing cell therapeutics for aging-related diseases. Key presentations include: April 20 - Kevin N. Ramdas discusses Lomecel-B clinical trial results at ICFSR, Boston. April 21 - Anthony Oliva presents on cognitive frailty. April 25 - Ramdas presents at the Latinos & Alzheimer’s Symposium. April 26 - Joshua Hare presents on aging and frailty at Longevity Leaders World Congress, London. The Company aims to advance its therapies into Phase 3 trials for conditions like Alzheimer's and Aging Frailty.

Longeveron Inc. (LGVN) announced a new Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Veterans Affairs (VA) to add a Miami VA clinical site to its Phase 2 Alzheimer’s Disease trial. This collaboration marks the third CRADA with the VA, which also includes studies on aging frailty and Covid-19. The Phase 2 trial, named CLEAR MIND, will explore the safety and efficacy of Lomecel-B in treating mild Alzheimer’s, enrolling 48 patients. Recent peer-reviewed data indicated that Lomecel-B shows promise in slowing cognitive decline and improving quality of life.

Longeveron Inc. (NASDAQ: LGVN) has appointed Dr. K. Chris Min as Chief Medical Officer, effective April 4, 2022. Dr. Min will oversee global clinical development and regulatory strategy, particularly focusing on advancing Lomecel-B through pivotal trials. He brings over a decade of industry experience, including roles at Enterin and Cerevel Therapeutics. The company aims to progress Lomecel-B's development for conditions like Alzheimer's and Hypoplastic Left Heart Syndrome, with clinical trials expanding to Asia.

Longeveron Inc. (NASDAQ: LGVN) announced positive results from a Phase 1 trial of Lomecel-B for Alzheimer's disease, published in Alzheimer’s & Dementia. The study met its primary safety endpoint, showing that Lomecel-B was well tolerated, with no serious side effects observed. Preliminary findings suggest Lomecel-B may slow cognitive decline and improve patient quality of life. A Phase 2 trial has commenced, exploring single vs. multiple doses. The study indicates a potential for Lomecel-B to address multiple Alzheimer’s pathology features, as highlighted by encouraging changes in cognitive and brain health assessments.